Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Zyvox I.v. Injection Generic Name & Formulations
Legal Class
Rx
General Description
Linezolid 2mg/mL; soln for IV infusion; sodium content 0.38mg/mL.
Pharmacological Class
Oxazolidinone.
See Also
How Supplied
Tabs—20, 30; Susp—150mL; Infusion bags (100mL, 300mL)—10
Manufacturer
Generic Availability
YES
Zyvox I.v. Injection Indications
Indications
Susceptible vancomycin-resistant E. faecium (VREF) infections, nosocomial and community-acquired pneumonia, complicated skin and skin structure infections (including diabetic foot infections) without osteomyelitis, uncomplicated skin and skin structure infections.
Limitations of Use
Not for treating Gram (–) infections. Safety and efficacy of Zyvox given for longer than 28 days have not been evaluated.
Zyvox I.v. Injection Dosage and Administration
Adult
Infuse inj over 30–120 mins; switch to oral form when appropriate. VREF: 600mg every 12hrs for 14–28 days. Pneumonia, complicated skin and skin structure: 600mg every 12hrs for 10–14 days. Uncomplicated skin and skin structure (oral forms only): 12–17yrs: 600mg every 12hrs; >17yrs: 400mg every 12hrs; both for 10–14 days. MRSA: 600mg every 12hrs.
Children
Infuse inj over 30–120 mins; switch to oral form when appropriate. Neonates <7 days: see full labeling. 0–11yrs: VREF: 10mg/kg every 8hrs for 14–28 days; pneumonia, complicated skin and skin structure: 10mg/kg every 8hrs for 10–14 days. Uncomplicated skin and skin structure (oral forms only): <5yrs: 10mg/kg every 8hrs; 5–11yrs: 10mg/kg every 12hrs; both for 10–14 days.
Zyvox I.v. Injection Contraindications
Contraindications
During or within 2 weeks of MAOIs (eg, phenelzine, isocarboxazid).
Zyvox I.v. Injection Boxed Warnings
Not Applicable
Zyvox I.v. Injection Warnings/Precautions
Warnings/Precautions
Not for treating catheter-related bloodstream infections or catheter-site infections. Uncontrolled hypertension, pheochromocytoma, thyrotoxicosis, carcinoid syndrome: not recommended. History of seizures. Monitor CBC's weekly (esp. if otherwise at risk). Consider discontinuing if myelosuppression occurs or worsens. Therapy >28 days. Peripheral and optic neuropathy. Monitor visual function if treatment ≥3 months and if new visual symptoms occur. Diabetes; monitor for hypoglycemia, if occurs, reduce dose or discontinue. Hyponatremia and/or SIADH; monitor serum sodium levels (esp. in elderly, those on diuretics, others at risk of). Phenylketonuria (oral susp form). Pregnancy. Nursing mothers: monitor infants.
Zyvox I.v. Injection Pharmacokinetics
See Literature
Zyvox I.v. Injection Interactions
Interactions
See Contraindications. Concomitant sympathomimetics (eg, pseudoephedrine), vasopressive agents (eg, epinephrine, norepinephrine), dopaminergics (eg, dopamine, dobutamine): not recommended. Risk of serotonin syndrome with concomitant SSRIs, trycyclic antidepressants, bupropion, buspirone, triptans, or opioids (eg, meperidine). Avoid large amounts of dietary tyramine (keep <100mg/meal). May be antagonized by carbamazepine, phenytoin, phenobarbital. Caution with myelosuppressants.
Zyvox I.v. Injection Adverse Reactions
Adverse Reactions
Diarrhea, vomiting, nausea, anemia, headache, rash, dizziness, pruritus, tongue discoloration, taste alteration; myelosuppression (eg, anemia, thrombocytopenia), lactic acidosis, C. difficile-associated diarrhea, hypoglycemia, blurred vision, convulsions.
Zyvox I.v. Injection Clinical Trials
See Literature
Zyvox I.v. Injection Note
Not Applicable
Zyvox I.v. Injection Patient Counseling
See Literature
